Caterina Mian
A5026090512- Thyroid Cancer Diagnosis and Treatment
- Thyroid Disorders and Treatments
- Pituitary Gland Disorders and Treatments
- Neuroendocrine Tumor Research Advances
- Thyroid and Parathyroid Surgery
- Adrenal and Paraganglionic Tumors
- S100 Proteins and Annexins
- Cancer, Hypoxia, and Metabolism
- BRCA gene mutations in cancer
- MicroRNA in disease regulation
- Cancer-related Molecular Pathways
- Growth Hormone and Insulin-like Growth Factors
- Hormonal Regulation and Hypertension
- Selenium in Biological Systems
- Genetic factors in colorectal cancer
- Neonatal Health and Biochemistry
- Vitamin D Research Studies
- Microtubule and mitosis dynamics
- Ophthalmology and Eye Disorders
- Neuroblastoma Research and Treatments
- Adrenal Hormones and Disorders
- Parathyroid Disorders and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Biomarkers in Disease Mechanisms
- Radiomics and Machine Learning in Medical Imaging
University of Padua
2016-2025
University of Milan
2017-2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2024
Istituto Nazionale Genetica Molecolare
2024
Azienda Ospedaliera di Padova
2022
March of Dimes
2022
Istituto Oncologico Veneto
2008-2019
Endocrinology Research Center
2003-2018
Qingdao University
2018
Johns Hopkins University
2014-2018
BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role PTC-related patient mortality has not been established.To investigate the relationship between mutation and mortality.Retrospective study of 1849 patients (1411 women 438 men) with median age 46 years (interquartile range, 34-58 years) an overall follow-up time 33 months 13-67 months) after initial treatment at 13 centers 7 countries 1978 2011.Patient deaths specifically caused by PTC.Overall, was 5.3%...
Purpose To investigate the prognostic value of BRAF V600E mutation for recurrence papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter study relationship between PTC in 2,099 patients (1,615 women 484 men), with median age 45 years (interquartile range [IQR], 34 to 58 years) follow-up time 36 months (IQR, 14 75 months). Results The overall prevalence 48.5% (1,017 2,099). occurred 20.9% (213 1,017) mutation–positive 11.6% (125 1,082) mutation–negative...
Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support.This study sought establish the clinicopathological risk major variants: conventional (CPTC), follicular-variant (FVPTC), and tall-cell (TCPTC).This was retrospective outcomes 6282 patients (4799 females 1483 males) from 26 centers The Cancer Genome Atlas...
Multiple endocrine neoplasia type 2 is characterized by germline mutations in RET. For exon 10, comprehensive molecular and corresponding phenotypic data are scarce. The International RET Exon 10 Consortium, comprising 27 centers from 15 countries, analyzed patients with for clinical-risk profiles. Presentation, age-dependent penetrance, stage at presentation of medullary thyroid carcinoma (MTC), pheochromocytoma, hyperparathyroidism were studied. A total 340 subjects 103 families, age 4–86,...
Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disease characterized by medullary thyroid carcinoma (MTC) associated 2A and 2B) or not familial MTC (FMTC) with other due to germline RET gene mutations. The prevalence of these rare diseases their corresponding mutations are unknown the small size study population.We collected data on 250 families hereditary followed in 20 different Italian centres.The most frequent amino acid substitution was Val804Met (19.6%) Cys634Arg (13.6%). A...
MicroRNAs (miRNAs) are involved in the pathogenesis of human cancers, including medullary thyroid carcinoma (MTC). The aim this study was to test hypothesis that different miRNA profiles related RET status and prognosis patients with hereditary MTC (hMTC) sporadic (sMTC).We analyzed expression nine miRNAs (miR-21, miR-127, miR-154, miR-224, miR-323, miR-370, miR-9*, miR-183, miR-375) by quantitative real-time-polymerase chain reaction 34 cases sMTC, 6 hMTC, 2 C-cell hyperplasia (CCH). We...
<h3>Importance</h3> Large studies investigating long-term outcomes of patients with bilateral pheochromocytomas treated either total or cortical-sparing adrenalectomies are needed to inform clinical management. <h3>Objective</h3> To determine the association vs adrenalectomy pheochromocytoma-specific mortality, burden primary adrenal insufficiency after adrenalectomy, and risk pheochromocytoma recurrence. <h3>Design, Setting, Participants</h3> This cohort study used data from a multicenter...
Calcitonin (CT) measurement is crucial to the early diagnosis and follow-up of medullary thyroid cancer (MTC). If evaluation stimulated CT levels required, a provocative test can be performed, being high-dose Ca recently reintroduced in clinical practice. Our objective was identify gender-specific thresholds for MTC large series patients who underwent test. A total 91 (49 females 42 males) (calcium gluconate, 25 mg/kg) before thyroidectomy both basal (bCT) (sCT) were compared with...
Purpose For the past 65 years, patient age at diagnosis has been widely used as a major mortality risk factor in stratification of papillary thyroid cancer (PTC), but whether this is generally applicable, particularly patients with different BRAF genetic backgrounds, unclear. The current study was designed to test factor. Patients and Methods We conducted comparative relationship between PTC-specific respect status 2,638 (623 men 2,015 women) median 46 years (interquartile range, 35 58...
Multifocality is often treated as a risk factor for papillary thyroid cancer (PTC), prompting aggressive treatments, but its prognostic value remains unestablished. To investigate the role of tumor multifocality in clinical outcomes PTC. Multicenter study relationship between and PTC 2638 patients (623 men 2015 women) with median [interquartile range (IQR)] age 46 (35 to 58) years (IQR) follow-up time 58 (26 107) months at 11 medical centers six countries. Surveillance, Epidemiology End...
Summary Objective Papillary thyroid cancers (PTCs) with no iodine uptake have an aggressive behaviour and a poor prognosis. The aim of our study was to characterize, at molecular level, subset PTC 131 ( I) uptake. Design methods Forty‐eight cancer tissues were divided into three groups: Group 1, 28 primary cancers; 2, 7 recurrences capable trapping I; 3, 13 incapable I. mRNA levels genes (sodium/iodide symporter NIS, thyroglobulin, thyroperoxidase pendrin) glycolytic metabolism GLUT‐1 ,...
Summary Objective Our study aimed to investigate whether physiological doses of selenium (Se) influence the natural course autoimmune thyroiditis (AIT). Design and Patients A total 76 consecutive patients (65F, 11M, median 43, range 15‐75 years) with AIT, normal or slightly elevated TSH fT4 within were divided into two groups: Group 0 (30 cases) was given no treatment while 1 (46 treated sodium selenite 80 μg/day as a single oral dose for 12 months. Thyroperoxidase thyroglobulin...
The evaluation of basal calcitonin (bCT) and stimulated (sCT) can be used for the diagnosis follow-up medullary thyroid cancer (MTC).The aim this study was to evaluate reliability high-calcium (Ca) test identify gender-specific thresholds MTC diagnosis.Patients with in remission (n=24) or persistence (n=18), RET gene mutations carriers (n=14), patients nodular goiter (n=69), healthy volunteers (n=16) were submitted pentagastrin Ca (25 mg/kg) tests.In all groups, levels (CT) by either...
Medullary thyroid carcinoma (MTC) derives from the parafollicular C cells, being sporadic in 75% of cases and familial 25%, due to RET proto-oncogene germinal mutations. In forms, stage at diagnosis is most important negative prognostic factor. The aim this study was evaluate impact molecular immunohistochemical markers MTC.We studied 60 patients with MTC. For each case, we sought somatic mutations primary cancer lymph node metastases. also underwent examination for Ki-67.A mutation found...
Precise risk stratification-based treatment of solitary intrathyroidal papillary thyroid cancer (SI-PTC) that is larger than 1.0 cm and 4.0 or less undefined.
Background: One of the most widely used risk stratification systems for estimating individual patients' persistent or recurrent differentiated thyroid cancer (DTC) is American Thyroid Association (ATA) guidelines. The 2015 ATA version, which has increased number patients considered at low intermediate risk, been validated in several retrospective, single-center studies. aims this study were to evaluate real-world performance system predicting response treatment 12 months after initial and...
How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined.To study whether LNM-associated PTC.We retrospectively analyzed the effect of LNM on PTC-specific with respect to status 2638 patients (2015 females and 623 males) from 11 centers 6 countries, median age 46 [interquartile range (IQR) 35-58] years follow-up time 58 (IQR 26-107) months.Overall, showed a modest wild-type but strong one patients. In conventional...